Eden Biodesign selected by Cancer Research UK to develop and manufacture two therapeutic candidates
Treatment of advanced intra-abdominal and head and neck cancer
Ad-hTR-NTR is a telomerase targeted adenoviral suicide gene therapy vector, which is active in telomerase expressing cancer cells. Activation of the hTR promoter in cancer cells drives bacterial nitroreductase expression and converts the inactive prodrug CB1954 into its active form leading to cell death.
Ad.CPG2 is a conditionally replication-competent oncolytic adenovirus that expresses carboxypeptidase G2 (Ad.CPG2). Activation of the prodrug (ZD2767P) by CPG2 releases a potent alkylating mustard preventing tumour proliferation by DNA cross-linking.
Under the terms of the agreements, Eden Biodesign will provide strategic advice to produce an effective development plan that will optimise the preclinical process with a view to expediting clinical manufacture and supply. Eden Biodesign will also develop the manufacturing process and associated analytical testing for these novel therapies. Depending on achieving preclinical development milestones, Eden Biodesign will provide cGMP (current Good Manufacturing Practices) production of Ad-hTR-NTR and Ad.CPG2 for the Phase I clinical trials. The complete project could take up to 18 months and reach £1.5 million in value.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.